Product Description
mRNA‑6231 is a lipid nanoparticle (LNP)‑encapsulated mRNA-based therapeutic that encodes for mutein human interleukin 2, fused to human serum albumin (HSA‑IL2m), with the goal of achieving enhanced selectivity toward T regulatory cells. IL-2 through preferential expansion of Tregs is hypothesized to play a central role in restoring immune homeostasis. (Sourced from: https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-First-Participant-Dosed-in-Phase-1-Study-of-Its-IL-2-mRNA-Therapeutic/default.aspx)
Mechanisms of Action: IL2 Agonist
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Moderna
Company Location: CAMBRIDGE MA 02139
Company CEO: Stéphane Bancel
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Autoimmune Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
mRNA-6231-P101 | P1 |
Completed |
Autoimmune Diseases |
2022-08-02 |